Aims: To prepare lamivudine (LAM)-loaded-nanoparticles (NPs) that can be used in
lung cancer treatment. To change the antiviral indication of LAM to anticancer.
Background: The development of anticancer drugs is a difficult process. One approach to
accelerate the availability of drugs is to reclassify drugs approved for other conditions as
anticancer. The most common route of administration of anticancer drugs is intravenous injection.
Oral administration of anticancer drugs may considerably change current treatment modalities of
chemotherapy and improve the life quality of cancer patients. There is also a potentially significant
Objective: To characterize the LAM-loaded-NPs and examine the anticancer activity.
Methods: LAM-loaded-NPs were prepared using Nano Spray-Dryer. Properties of NPs were
elucidated by particle size (PS), polydispersity index (PDI), zeta potential (ZP), SEM,
encapsulation efficiency (EE%), dissolution, release kinetics, DSC and FT-IR. Then, the anticancer
activity of all NPs was examined.
Results: The PS values of the LAM-loaded-NPs were between 373 and 486 nm. All NPs prepared
have spherical structure and positive ZP. EE% was in a range of 61-79%. NPs showed prolonged
release and the release kinetics fitted to the Weibull model. NPs structures were clarified by DSC
and FT-IR analysis. The results showed that the properties of NPs were directly related to the
drug:polymer ratio of feed solution. NPs have potential anticancer properties against A549 cell line
at low concentrations and non-toxic to CCD 19-Lu cell line.
Conclusion: NPs have potential anticancer properties against human lung adenocarcinoma cells
and may induce cell death effectively and be a potent modality to treat this type of cancer. These
experiments also indicate that our formulations are non-toxic to normal cells. It is clear that this
study would bring a new perspective to cancer therapy.